University of Patras
Ανασυνδυασμένα τμήματα του ανθρώπινου νικοτινικού υποδοχέα για την κατανόηση των παθογενετικών μηχανισμών της βαριάς μυασθένειας
Abstract
dc:descriptionAcetylcholine receptors (AChRs) are integral membrane proteins that respond to the binding of acetylcholine (ACh), which is synthesized, stored and finally released by cholinergic neurons. Like other transmembrane receptors, AChRs have been classified according to either their pharmacological properties or their relative affinities for various molecules, and can therefore be further divided into: i) nicotinic AChRs, which are particularly responsive to nicotine and ii) muscarinic AChRs, which are particularly responsive to muscarine. AChRs are involved in myasthenia gravis (MG) and many other physiological disorders, mainly affecting the central and peripheral nervous system. In MG, autoantibodies are directed against the nicotinic AChR at the neuromuscular junction. The disease is characterized by various symptoms, including muscle weakness and fatigability, due to defective neuromuscular transmission. To obtain an insight into the role of the various anti-AChR antibody specificities in MG, we isolated and studied the in vitro and in vivo activity of autoantibodies targeting individual AChR subunits. Using recombinant proteins corresponding to extracellular domains (ECDs) of individual AChR subunits as immunoadsorbents; we isolated autoantibodies which specifically bind to these subunits. We then used the well established TE671 human muscle cell line to examine the in vitro functions of subunit-specific autoantibody populations through their ability to induce nAChR antigenic modulation. Isolated subunit-specific autoantibodies were also used to determine their capacity to passively transfer experimental MG into lab animals. Our results clearly demonstrated that autoantibodies against the α1 or β subunit can cause AChR loss via antigenic modulation in a dose-dependent manner, the anti-α1 autoantibodies being much more effective than the anti-β autoantibodies. Furthermore, we showed that the autoantibody-depleted sera were much less effective, or were completely inactive, at causing AChR loss. In in vivo experiments, the administration of MG sera derivatives to lab animals showed that sera enriched in anti-α1 autoantibodies, as well as the corresponding pure anti-α1 autoantibodies from two individuals, are efficient in inducing MG like symptoms to the animals. A single serum contained almost 100% anti-β antibodies and the corresponding purified antibodies did not cause any clinical MG symptoms. The depleted fraction of MG sera tested, induced mild symptoms or no symptoms were observed, and this is in agreement with the in vitro results, strongly suggesting that the anti-AChR autoantibodies in MG sera and mainly the anti-α1 specificities are the sole pathogenic factor in anti-AChR antibody-seropositive MG.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sideris, Sotirios
- Σιδέρης, Σωτήριος
Subjects
dc:subject × 14- Βαριά μυασθένεια
- Νικοτινικός υποδοχέας ακετυλοχολίνης
- Ανασυνδυασμένο πολυπεπτίδιο
- Αυτοαντισώματα
- Αντιγονική τροποποίηση
- Myasthenia gravis (MG)
- Nicotinic acetylcholine receptor
- Recombinant polypeptide
- Autoantibodies
- Antigenic modulation
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17796